

[31] The method of [29] or [30], wherein two or more kinds of T cell activating ligands are contacted.

[32] The method of any of [29] to [31], wherein the aforementioned nucleic acid delivery carrier is a lipid nanoparticle or a liposome.

[33] The method of any of [29] to [32], wherein the aforementioned nucleic acid delivery carrier comprises a nucleic acid suppressing expression of a T cell activation inhibitory factor and/or a nucleic acid encoding a T cell activation promoting factor.

[34] The method of any of [29] to [33], wherein the aforementioned nucleic acid comprises a nucleic acid encoding CAR or TCR.

[35] The method of any of [29] to [34], wherein the method is performed ex vivo.

[36] A nucleic acid delivery carrier having at least one kind of T cell activating ligand added to its surface.

[37] The nucleic acid delivery carrier of [36], wherein the aforementioned T cell activating ligand includes an antibody to CD3 and/or an antibody to CD28.

[38] The nucleic acid delivery carrier of [36] or [37], wherein the aforementioned nucleic acid delivery carrier has two or more kinds of T cell activating ligands added to a surface thereof.

[39] The nucleic acid delivery carrier of any of [36] to [38], wherein the aforementioned nucleic acid delivery carrier is a lipid nanoparticle or a liposome.

[40] The nucleic acid delivery carrier of any of [36] to [39], comprising, in the inside, a nucleic acid suppressing expression of a T cell activation inhibitory factor and/or a nucleic acid encoding a T cell activation promoting factor.

[41] The nucleic acid delivery carrier of any of [36] to [40], comprising, in the inside, a nucleic acid encoding CAR or TCR.

[42] A medicament comprising the nucleic acid delivery carrier of any of [36] to [41].

[43] A T cell into which a nucleic acid has been delivered by the method of any of [15] to [21].

[44] A medicament comprising the T cell of [43].